Skip to main content
Medical information Clinical review pending

Genetic Testing

EFHC1 Gene Epilepsy Juvenile Absence Type 1 Genetic Test

Genetic test using Next-Generation Sequencing (NGS) to identify mutations in the EFHC1 gene associated with Juvenile Absence Epilepsy Type 1. Aids in diagnosis and treatment planning.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), Extracted DNA, or one drop of blood on an FTA card.
Results
3 to 4 weeks. Confirm with the laboratory before booking.
Preparation
Clinical history of the patient is required. A genetic counseling session to draw a pedigree chart of affected family members is recommended before testing. Confirm with the laboratory before booking.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the EFHC1 Gene Epilepsy Juvenile Absence Type 1 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of suspected Juvenile Absence Epilepsy Type 1
  • ✓Individuals with unexplained absence seizures
  • ✓Family history of Juvenile Absence Epilepsy Type 1
  • ✓Genetic predisposition to epilepsy
  • ✓Guiding treatment decisions
  • ✓Family planning and genetic counseling
02

In plain language

What this test helps you understand

Identifies mutations in the EFHC1 gene associated with Juvenile Absence Epilepsy Type 1, aiding in diagnosis, prognosis, and management.
The EFHC1 Gene Epilepsy Juvenile Absence Type 1 NGS Genetic DNA Test is a diagnostic tool used to identify genetic mutations linked to juvenile absence epilepsy. This test is valuable for individuals experiencing unexplained seizures, helping to clarify their condition and guide appropriate treatment strategies.

This genetic test employs Next-Generation Sequencing (NGS) technology to analyze the EFHC1 gene. It specifically looks for mutations that may contribute to the development of juvenile absence epilepsy, a neurological condition often characterized by brief, sudden lapses in consciousness.

Individuals experiencing symptoms like frequent absence seizures, those with a family history of epilepsy, or children with unexplained seizures might benefit from this test. Patients with a clinical history suggesting a genetic predisposition to epilepsy are also encouraged to consider testing.

Benefits of this test include accurate diagnosis of juvenile absence epilepsy, enabling informed treatment planning and management. It also helps in understanding potential hereditary risks for family members and provides access to genetic counseling and support.

After receiving your results, a healthcare professional will explain the findings. A positive result indicating a mutation may suggest a hereditary risk, while a negative result can help rule out genetic causes related to the EFHC1 gene. Discussing your results with a neurologist or genetic counselor is essential for a complete understanding and to determine next steps.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationClinical history of the patient is required. A genetic counseling session to draw a pedigree chart of affected family members is recommended before testing. Confirm with the laboratory before booking.
SampleBlood sample (EDTA tube), Extracted DNA, or one drop of blood on an FTA card.
MethodologyNext-Generation Sequencing (NGS) of the EFHC1 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes only the EFHC1 gene. Other genes or factors may be involved in epilepsy. A negative result does not completely rule out a genetic cause. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

It is a type of epilepsy characterized by brief, sudden lapses in consciousness (absence seizures), often starting in childhood or adolescence. It can have a genetic basis.
The EFHC1 gene provides instructions for making a protein important for the function of certain nerve cells in the brain. Mutations in this gene are linked to Juvenile Absence Epilepsy Type 1.
Individuals experiencing frequent absence seizures, children with unexplained seizures, or those with a family history of this type of epilepsy may be candidates for this test.
Your doctor or a genetic counselor will interpret the results with you. They will explain what the findings mean for your diagnosis, treatment, and potential risks for family members.
Insurance coverage varies. Please check with your insurance provider regarding coverage for genetic testing.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp